The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism

Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism

(2016) Hong Li et al.   PHARMACEUTICAL BIOLOGY

Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma

(2015) C. Schmithals et al.   CANCER RESEARCH

Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib

(2015) Camille Tlemsani et al.   Expert Opinion on Drug Metabolism & Toxicology

Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group

(2015) AeRang Kim et al.   PEDIATRIC BLOOD & CANCER

Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma

(2015) Miki Shimada et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity

(2014) Tina B. Gillani et al.   CHEMICAL RESEARCH IN TOXICOLOGY

B-Raf Regulation of Integrin α4β1-mediated Resistance to Shear Stress through Changes in Cell Spreading and Cytoskeletal Association in T Cells

(2014) Wells S. Brown et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Sorafenib and triptolide as combination therapy for hepatocellular carcinoma

(2014) Osama A. Alsaied et al.   SURGERY

Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors

(2013) M Ahmadi et al.   BRITISH JOURNAL OF PHARMACOLOGY

The role of cell signalling in the crosstalk between autophagy and apoptosis

(2013) Laurence A. Booth et al.   CELLULAR SIGNALLING

Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes

(2013) Xiao-Yi Qi et al.   FOOD AND CHEMICAL TOXICOLOGY

Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role

(2013) Vijaya R Bhatt et al.   Future Oncology

Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice

(2013) Yunching Chen et al.   HEPATOLOGY

Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis

(2013) Junaid Abdulghani et al.   PLoS One

Ontogeny and Sorafenib Metabolism

(2012) E. I. Zimmerman et al.   CLINICAL CANCER RESEARCH

Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat

(2011) Xue-qing Wang et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Saturable absorption of sorafenib in patients with solid tumors: a population model

(2011) Marilyne Hornecker et al.   INVESTIGATIONAL NEW DRUGS

Absorption Enhancement Effect of Acylcarnitines through Changes in Tight Junction Protein in Caco-2 Cell Monolayers

(2010) Nobuyuki Doi et al.   Drug Metabolism and Pharmacokinetics